As expected, our study found that OXA activates the PI3K/AKT signaling pathway, promoting the proteasomal degradation of p53 in both primary and acquired resistance xenografts, thereby exacerbating OXA resistance in CRC cells. This evidence concerns the gene AKT1 and colorectal carcinoma.